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Abstract
Background: Farrerol, isolated from rhododendron, has been shown to have the anti-bacterial activity, but no details on the
anti-inflammatory activity. We further evaluated the effects of this compound in two experimental models of lung diseases.
Methodology/Principal Findings: For the asthma model, female BALB/c mice were challenged with ovalbumin (OVA), and
then treated daily with farrerol (20 and 40 mg/kg, ip) as a therapeutic treatment from day 22 to day 26 post immunization.
To induce acute lung injury, female BALB/c mice were injected intranasally with LPS and treated with farrerol (20 and
40 mg/kg, i.p.) 1 h prior to LPS stimulation. Inflammation in the two different models was determined using ELISA,
histology, real-time PCR and western blot. Farrerol significantly regulated the phenotype challenged by OVA, like cell
number, Th1 and Th2 cytokines levels in the BALF, the OVA-specific IgE level in the serum, goblet cell hyperplasia in the
airway, airway hyperresponsiveness to inhaled methacholine and mRNA expression of chemokines and their receptors.
Furthermore, farrerol markedly attenuated the activation of phosphorylation of Akt and nuclear factor-kB (NF-kB) subunit
p65 both in vivo and in vitro. However, farrerol has no effect on the acute lung injury model.
Conclusion/Significance: Our finding demonstrates that the distinct anti-inflammatory effect of farrerol in the treatment of
asthma acts by inhibiting the PI3K and NF-kB pathway.
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Introduction
The lung is a very complex immunologic organ and responds in
a variety of ways to inhaled antigens, infectious materials or
saprophytic agents. Pulmonary disorders can be classified
according to the immune responses which they induce. Innate
immunity includes the presence of PMNs, an increase in
procoagulant activity and the secretion of IL-8, which are
important mediators in diseases, such as pneumonia, acute lung
injury and its more severe form, acute respiratory distress
syndrome (ARDS). On the other hand, adaptive immune
conditions like asthma are characterized by adaptive responses
which including Th1 or Th2, eosinophils, antibody mediated [1].
Airway inflammation is present in acute lung injuries and asthma
caused by different responses [2,3]. Different results from
experiments with infectious and non-infectious mouse airway
inflammatory models show a distinct anti-inflammatory role of
chemicals that can later be translated for use in the clinic [4,5].
Mammalian Toll-like receptor (TLR) proteins derive their name
from the Drosophila Toll protein, which has ten receptors to date
[6]. Some studies have revealed that TLR proteins utilize a similar
signaling cascade that ultimately culminates in the activation of
NF-kB, activator protein-1, phosphatidylinositol 3-kinase, and
mitogen-activated protein (MAP) kinases which play a critical role
in pulmonary infectious disease, inflammation and allergic asthma
[7,8]. A better understanding of the roles of the signals regulating
lung disease will aid in the promotion of new therapies for the
associated symptoms. NF-kB is a key transcriptional factor
involved in regulating the expression of proinflammatory media-
tors, including cytokines, chemokines, and adhesion molecules,
thereby playing a critical role in mediating inflammatory responses
[9,10]. PI3Ks is a large family of signaling kinases involved in
the inflammatory process. PI3Ks mediate key signal transduction
reactions during immune and inflammatory responses and
thus represent an attractive target for therapeutic development
in various inflammatory diseases [11,12]. There is increasing
evidence that PI3Ks contribute to the pathogenesis of asthma by
regulating the expression and activation of inflammatory media-
tors, inflammatory cell recruitment and immune cell function [13].
In folk medicine, plants have long been used to treat a wide
range of pathologies, such as cancers, inflammatory diseases and
asthma. The flavonoids are a large group of polyphenolic natural
products that are widely distributed in higher plants, which are
well known to have a variety of therapeutic activities such as
against cancers, tumors, inflammation and cardiovascular disease
[14]. Some flavonoids isolated from the roots of Rhododendron
mucronulatum Turzaninov were reported to be a potential
antiinflammatory agents based on the results of dose-dependently
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PGE2 [15]. Farrerol (structure shown in Fig. 1), a new kind of 2,3-
dihydro-flavonoid drug, is also isolated from rhododendron, which
belongs to a traditional Chinese herbal medicine [16]. It has been
shown to have the anti-bacterial activity, but no details on the anti-
inflammatory activity [17].
Inflammation is a hallmark of many human diseases, including
pulmonary inflammatory diseases (e.g., chronic obstructive
pulmonary disease, and asthma), infectious diseases and cancer.
Steroids and cyclooxygenase inhibitors have long been used as the
main therapeutical anti-inflammatory agents, but they are
frequently associated with significant detrimental effects in patients
[18,19]. Thus, there is an urgent need for the development of
unique anti-inflammatory drugs. An understanding of the airway
inflammation in the lung in infectious and non-infectious lung
diseases is critical to the development of new and innovative
therapies for allergic and inflammatory lung disease.
Results
Farrerol Suppresses Ovalbumin-induced Inflammatory
Cell Recruitment
The inflammatory cell levels (i.e., total cells, eosinophils,
neutrophils, macrophages and lymphocytes) in the bronchoalve-
olar lavage fluid were significantly elevated in OVA-challenged
mice versus control mice. Farrerol (20 and 40 mg/kg) decreased
the total cell number and eosinophils in a dose-dependent manner
(Fig. 2), as compared with the dexamethasone control, but only
slightly decreased the number of infiltrating neutrophils and
macrophages.
Farrerol Suppresses Airway Inflammation, Goblet Cell
Hyperplasia and Mucus Production
To assess the anti-inflammatory effect of farrerol on the airway,
histopathological studies were performed. Inflammatory cell
infiltration in the peribronchial and perivascular areas (H&E
staining), mucus overproduction and goblet cell hyperplasia (as
detected by AB-PAS staining) were observed in OVA-challenged
mice (Fig. 3A and 3B). Farrerol treatment (20 or 40 mg/kg) dose-
dependently and markedly reduced the degree of inflammatory
cell infiltration in the peribronchial and perivascular areas (Fig. 3A
and 3C), mucus overproduction and goblet cell hyperplasia
(Fig. 3B and 3D).
Farrerol Regulates Ovalbumin-induced Bronchoalvelar
Lavage Fluid T Helper 1 and T Helper 2 Cytokine Levels
and Serum Immunoglobulin Production in vivo
OVA-sensitized mice showed a notable increase in IFNc, IL-10,
IL-4, IL-5, IL-13 and eotaxin levels in the BAL fluid as compared
with a saline aerosol control (Figure 4). Farrerol significantly
reduced IL-4, IL-5, IL-13, CCL11 and increased IFNc levels in a
dose-dependent manner as compared with the DMSO control.
However, there was no significant difference in IL-10 level which
suggest farrerol can not suppress Th2 cytokines via upregulating
IL-10. This finding suggested that farrerol can regulate the
predominant Th1 and Th2 response in our OVA-induced mouse
asthma model.
To further evaluate whether farrerol could modify an ongoing
OVA-specific Th2 response in vivo, serum levels of total IgE and
OVA-specific IgE were determined using ELISA. Farrerol (20 and
40 mg/kg) significantly suppressed OVA-specific IgE, which was
induced by OVA.
Effect of Farrerol on Ovalbumin-induced Airway
Hyperresponsiveness
To investigate the effect of farrerol on AHR in response to
increasing concentrations of methacholine, we measured both RL
and Cdyn in mechanically ventilated mice. OVA-challenged mice
developed AHR, typically reflected by a high RL and low Cdyn
(Figure 5). Farrerol treatment (20 and 40 mg/kg) dramatically
reduced RL and restored Cdyn in OVA-challenged mice in
response to methacholine.
Effect of Farrerol on OVA-induced Chemokines and
Inflammatory Gene Expression in Allergic Airway
Inflammation
Whole-lung mRNA expression was determined using quantita-
tive RNA analysis. The levels of the chemokines CCL5 and
CCL11 and their receptors CCR1 and CCR3 were greatly
enhanced in the OVA group in comparison with the control
group. We found that farrerol treatment (20 and 40 mg/kg)
significantly reduced the chemokines and the upregulation of their
receptors after OVA challenge (Fig. 6).
Figure 1. Chemical structure of farrerol.
doi:10.1371/journal.pone.0034634.g001
Figure 2. Effects of farrerol on OVA-induced inflammatory cell
recruitment and mucus hyper-secretion. Inflammatory cell counts
in BALF obtained from sensitized mice 24 h after the last farrerol
treatment. Differential cell counts were identified eosinophil (Eos),
macrophage (Mac), neutrophil (Neu) and lymphocyte (Lym).
doi:10.1371/journal.pone.0034634.g002
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recruitment of inflammatory cells, airway inflammation and
mucus hypersecretion, we further investigated the mRNA
expression of E-selectin, AMCase, Ym1, Ym2 and Muc5ac,
which have been shown to play vital roles in airway inflammation
and remodeling. Pretreatment with farrerol also strongly suppress
the expression of E-selectin, AMCase, Ym1, Ym2 and Muc5ac in
the allergic airway.
Effect of Farrerol on MAPK, Phosphatidylinositol 3-kinase
Activation in vivo
To evaluate the effect of farrerol on the activation of MAPK
and PI3K in the mouse asthma model, we homogenized the lung
tissue to obtain a total protein lysate. The OVA-challenged mice
showed significant upregulation of p-Akt, p-p70S6K, p-p38,
pERK, and p-JNK. Farrerol can suppress the OVA-induced
upregulation of p-Akt and p-p70 S6K in a dose-dependent
manner. However, there was no significant downregulation of
MAPK (Fig. 7).
Effect of Farrerol on NF-kB Activation, IkBa
Phosphorylation and Degradation in vivo
To evaluate the effect of farrerol on NF-kB activation in a
mouse asthma model, we homogenized the lung tissue to obtain
total, nuclear and cytoplasmic proteins. In our study, Fig. 8A
showed that OVA-challenged mice showed a notably increased
nuclear protein level and a decreased cytoplasmic protein level,
compared to PBS-challenged mice. Farrerol treatment significant-
ly attenuated these alterations in a dose-dependent manner
(*p,0.05, **p,0.01). To gain further insight into the mechanism
of farrerol-mediated regulation of NF-kB in vivo, we examined the
effect of farrerol on IkBa phosphorylation and degradation. As
shown in Fig. 8B, OVA-induced IkBa degradation was
significantly blocked by pretreatment with farrerol, which was
related to IkBa phosphorylation.
Effect of Farrerol on the Cytokines, PI3K and NF-kB
Activation in vitro
To assess whether farrerol treatment could directly affect
lymphocyte function, we examined anti-CD3/CD28-challenged
Figure 3. Effects of farrerol on lung tissue eosinophilia and mucus production. Histologic examination of lung tissue eosinophilia using HE
staining (A) and mucus secretion using AB-PAS staining (B) from: (a) PBS-challenged mice; (b) OVA-challenged mice; (c) OVA-challenged mice treated
with farrerol (20 mg/kg); (d) OVA-challenged mice treated with farrerol (40 mg/kg); (e) OVA-challenged mice treated with dexamethasone (2 mg/kg,
magnification6400). Quantitative analyses of inflammatory cell infiltration (C) and mucus production (D) in lung sections were performed as
previously described [35]. At least 5 different fields for each lung section was performed to score the inflammatory cells and goblet cells. Mean scores
were obtained from 5 mice. **P , 0.01. vs. OVA.
doi:10.1371/journal.pone.0034634.g003
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tions in the culture supernatant of Th2 cells were measured by
sandwich ELISA (Fig. 9A). Treatment with farrerol (5 and
20 mg/L) can markedly decreased IL-4, IL-5 and IL-13 levels in
the cell supernatant which induced by anti-CD3/CD28 (*p,0.05,
**p,0.01). we also evaluated the effect of farrerol on p-Akt and
the p-IkBa as a marker of NF-kB activation. We found that anti-
CD3 stimulation can induce the expression of p-Akt, p-p70S6K
and p- IkBa. As shown in Fig. 9B, pretreatment with farrerol
downregulated p-Akt, p-p70S6K and IkBa phosphorylation and
then block the of IkBa degradation.
Effect of Farrerol on LPS-induced Acute Lung Injury
The total cell counts, differential cell counts, TNF-a, IL-6 and
IL-8 in the BALF were evaluated 24 h after LPS administration.
AsshowninFig.S1, LPScanmarkedlyincreasethenumber oftotal
cells, neutrophils, macrophages, as well as the levels of TNF-a, IL-6
and IL-8 compared with the control group. However, farrerol does
nothaveanyeffectonthisincreasecomparedtothedexamethasone
group. Besides, farrerols can not decrease the upregulation of NF-
kB, p-AKT, and MAPKs (Fig. S2).
Discussion
Pulmonary disorders can be grouped according to whether the
primary immune responses are characterized by innate or
adaptive immune responses. In recent decades, using molecular,
cellular assays together with knockout or transgenic animals, we
have got more information about the immunological factors that
contribute to the development pulmonary disorders. The immu-
nologic features of pulmonary disorders can be used to categorize
various conditions and provide focus for potential innovative
therapies. Phytochemical and pharmacological studies have
identified many potential anti-inflammatory substances, especially
those derived from plants used in folk medicine, so natural
products are becoming increasingly important as sources of
pharmacotherapeutics, either for the treatment of infectious lung
diseases or the theatment of noninfectious lung diseases [4,20,21].
In this study, we used two lung disease models: acute lung injury,
characterized by innate immune responses and allergic asthma,
involving adaptive immune responses, to demonstrate that farrerol
can markedly reduce the allergic airway inflammation and AHR
for allergic asthma model, but has no effect in an acute lung injury
model.
Figure 4. Effects of farrerol on cytokine and chemokine levels in BALF and serum immunoglobulin production in vivo. BALF and
blood were collected and centrifuged 24 hours after the last OVA challenge, and the supernatants and serum were measured by ELISA. Results of IgE
in serum (mean6SEM n=10) are expressed as Optical Density values and are representative of at least three independent in vivo experiments.
*p,0.05, **p,0.01 vs. OVA.
doi:10.1371/journal.pone.0034634.g004
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presence of internal and external substances, which is character-
ized by innate immunity and adaptive immunity. Asthma is
characterized by AHR and chronic airway inflammation, which
includes the infiltration of inflammatory cells into lung tissues,
mucus overproduction, allergen-specific IgE, the over-expression
of Th2-mediated cytokines, including interleukin (IL)-4, IL-5 and
IL-13, and chemokines such as CCL11 (CCL11) and RANTES
(CCL5). In contrast, Th1 cytokines such as interferon-c (IFN-c),
can inhibit the development of allergic lung inflammation through
down-regulating Th2 responses [22]. The predominant inflam-
matory cell recruited into asthmatic lung tissue is the eosinophil,
which is associated with the production of IL-5. However,
macrophages, the minor inflammatory cell recruited into asth-
matic lung tissue, can produce IL-10 to suppress Th2 cytokine
production and eosinophilia but augments airway reactivity. Acute
lung injury is characterized by systemic airway inflammatory
response including cytokines (e.g., TNF-a, IL-6, IL-8), chemo-
kines, pro-inflammatory mediators and a variety of cells, which
regulate the migration and pulmonary infiltration of neutrophils
into the interstitial tissue [23]. Neutrophils are an important
component of the inflammatory response that characterizes acute
lung injury (ALI) [24]. In addition, PI3K contribute to the
pathogenesis of asthma or acute lung injury by influencing the
recruitment of eosinophils or neutrophils [12]. In previous report,
farrerol has been reported to block FBS-induced vascular smooth
muscle cells proliferation by acting as a estrogen receptors agonist
[25]. In addition, estrogen has been shown to aggravates
inflammation in pseudomonas aeruginosa pneumonia in cystic
fibrosis mice via increasing the total white blood cell counts and
neutrophils, Th1 cytokines (TNF-a and IL-6) Th2 cytokines (IL-5)
and extaxin [26]. From our study, we can conclude that farrerol
can reduce the number of total inflammatory cells and eosinophils
in BAL fluid; IL-4, IL-5 and IL-13 levels in BAL fluid, OVA-
specific IgE levels in serum; mRNA levels of CCL5, CCL11,
CCR3, CCR5, E-selectin, chitinases, and Muc5ac in lung tissues.
Furthermore, as IFN-c was evoked by farrerol in the lung of mice
this cytokine may act to further suppress type 2 pulmonary
inflammation. After OVA challenge, farrerol can also inhibit the
expression of p-Akt. However, farrerol does not have any effect on
TNF-a, IL-6, and IL-8, which are induced in acute lung injury. So
these result suggested that on the one hand, farrerol maybe act as
an estrogen receptors agonist to result in aggravating the
inflammation in infectious inflammation model; on the other
hand, farrerol play an important role in reducing airway
inflammation in uninfectious inflammation model. The distinct
effect of farrerol on the different airway inflammation maybe
depending on its potential as an estrogen receptors or not.
The transcription factor NF-kB regulates the expression of a
large number of genes in response to infection, inflammation
and other endogenous and exogenous stressors. Under resting
conditions, NF-kB is held inactiveby IkB. However, NF-kB can
be activated by some stimulation of various receptors including
TNF receptor, Toll-like receptors (TLRs) and T-cell receptor
(TCR). Persistent activation of NF-kB is central to the
pathogenesis of many inflammatory lung disorders including
chronic obstructive pulmonary, asthma, pneumonia, and acute
lung injury. In our study, farrerol can inhibit NF-kB activation
induced by OVA in an allergic asthma model, but not in acute
lung injury model, which suggests that the decreased NF-kB
activation could account for the inhibition of airway inflamma-
tion and AHR.
Corticosteriods have a puissant anti-inflammatory action and
have a central role in the treatment for asthma [27]. However,
prolonged use of corticosteriods, especially at higher doses, has
been accompanied by concerns about both systemic and local
side effects [28]. Date in this study indicates a potential
therapeutic value for farrerol in the treatment of allergic
asthma. In the context of current treatments for allergic asthma,
future experimental studies are needed to address if farrerol can
reduce corticosteriods dosage using combinations of both drugs.
Materials and Methods
Reagents
The mAbs against mouse CD3, CD28, IL-4, IL-5, IL-13,
TNFa, IL-6, IL-8, IFN-c and IL-10 ELISA kits were purchased
from Biolegend (California, USA). CCL11 mouse ELISA kit was
Figure 5. Effects of farrerol on OVA-induced AHR. Airway responsiveness of mechanically ventilated mice in response to aerosolized
methacholine was measured 24 h after the last saline aerosol or OVA aerosol with pretreatment of either DMSO or Farrerol (20 and 40 mg/kg). AHR is
expressed as percentage change from the baseline level of (A) dynamic compliance (Cdyn, n=6 mice) and (B) lung resistance (RL, n=5 mice). Cdyn
refers to the distensibility of the lung and is defined as the change in volume of the lung produced by a change in pressure across the lung. RL is
defined as the pressure driving respiration divided by flow. *p,0.05, **p,0.01 vs. OVA.
doi:10.1371/journal.pone.0034634.g005
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purchased from Santa Cruz (Santa Cruz, CA, USA) and Cell
Signaling Technology Inc. (Beverly, MA). Dimethy sulfoxide
(DMSO) and OVA (Grade V) were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Farrerol (analytical grade,
purity $98%) was obtained from the National Institute for the
Controlof Pharmaceutical and Biological Products (Beijing, China).
Animals
Female BALB/c mice, weighing approximately 18 to 20 g, were
purchased from Shanghai Jingke Industrial Co., LTD (Certificate
SCXK2003-0003) (Shanghai, China) and bred under specific
pathogen-free conditions. The mice were housed in microisolator
cages and received food and water ad libitum. All animal studies
were conducted according to the experimental practices and
standards approved by the Animal Welfare and Research Ethics
Committee at Jilin University.
Sensitization and Challenge with OVA and Treatment
These mice were divided into six groups (n=10) and were
sensitized with 20 mg ovalbumin adsorbed in 100 mg/ml of Imject
Alum by i.p. injection on days 0, 7, 14 (general sensitization) in all
mice. On day 14, mice are anesthetized and 100 mg of OVA in
50 ml of PBS administered intranasally in all mice except negative
control sensitized with PBS. Mice are again anesthetized before
being challenged with 50 mg of OVA in 50 ml of PBS on each of
days 25–27. On days 25–27, farrerol at 20 and 40 mg/kg and
dexamethasone (2 mg/kg) were given by i.p. injection 1 h prior to
OVA administration.
Murine Model of LPS-induced ALI
LPS-induced ALI was induced as previously described [29].
Briefly, mice were anesthetized and challenged with intranasal
10 mg of LPS in 50 ml PBS. Control mice were given 50 ml PBS
i.n. instillation without LPS. Farrerol at 20 and 40 mg/kg and
dexamethasone was i.p. injected 1 h prior to LPS administration.
Collection of Blood and Bronchoalveolar Lavage
At selected times after the last inhalational exposure, mice were
anesthetized and bled via the brachial plexus for the collection of
blood samples used to estimate the levels of total IgE and OVA-
specific IgE. Bronchoalveolar lavage (BAL) was performed twice
Figure 6. Effect of farrerol on OVA-induced inflammatory gene expression in allergic airway inflammation. Lung tissues were collected
24 hours after the last OVA aerosol challenge. The mRNA in whole-lung extracts was measured by real-time PCR. Treatment with farrerol (20 and
40 mg/kg) reduced OVA-induced mRNA expression in the lung. The values represent the mean6SEM of 10 animals in each group. **P,0.01. vs. OVA.
doi:10.1371/journal.pone.0034634.g006
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34634Figure 7. Effect of farrerol on Akt, P70S6K, and MAPK activation in vivo. Immunoblotting of Akt, P70S6K, and MAPK in proteins extracts of
lung tissues isolated from mice 24 hours after the last OVA challenge pretreated with 20 or 40 mg/kg farrerol. b-actin was used as an internal control.
Experiments were repeated three times and similar results were obtained.
doi:10.1371/journal.pone.0034634.g007
Figure 8. Effect of farrerol on the activation of NF-kB and IkBa phosphorylation and degradation in vivo. (A) Effect of farrerol treatment
on nuclear translocation of NF-kB. Nuclear and cytoplasmic proteins from lung were analyzed by western blot with specific antibodies. (B) Effect of
oxytetracycline treatment on IkBa phosphorylation and degradation. Total cellular proteins from lung were analyzed by western blot with specific
antibodies. b-Actin was used as an internal control. Experiments were repeated three times and similar results were obtained.
doi:10.1371/journal.pone.0034634.g008
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centrifuged and the supernatants were used for cytokine and
chemokines measurements. Cell pellets were resuspended in 1 ml
of PBS and used for total and differential cell counts as described
[30].
Lung Histology
Histopathological evaluations were performed on mice. Left
lungs were removed by dissection and fixed in 4% paraformal-
dehyde. Lung tissues were sectioned, embedded in paraffin, and
cut into 3 mm sections. Tissue sections were then stained with
hematoxylin and eosin stain (H&E) for general morphology [31]
and with AB-PAS for the identification of goblet cells in the
epithelium [32].
Measurements of Airway Hyperresponsiveness
Airway responsiveness was assessed by methacholine-induced
airway resistance (RL) and lung compliance (Cdyn) using a whole-
body plethysmograph chamber (Buxco, Sharon, CT) as described
[33]. Mice were anesthetized with pentobarbital sodium (100 mg/
kg) and tracheotomy was performed as described [33]. The
internal jugular vein was cannulated and connected to a
microsyringe for aerosolized methacholine administration. Base-
line lung resistance, dynamic compliance, and responses to
Figure 9. Effect of farrerol (20 and 40 mg/kg) on the IL-4, IL-5, and IL-13, Akt, P70S6K, and IkBa phosphorylation and degradation
in vitro. The supernatant of Th2 cells was measured by sandwich ELISA. The values represent the mean6SEM of three independent in vitro
experiments. Th2 cells were cultured with anti-CD3 (5 mg/ml) for 1 h (1 mg/L), total cellular proteins were analyzed by western blot with specific
antibodies. b-Actin was used as an internal control. Experiments were repeated three times and similar results were obtained.
doi:10.1371/journal.pone.0034634.g009
Table 1. Primer sets for reverse transcriptase-polymerase chain reacion analysis.
Targets Forward Reverse
CCL11 AAACCATAAACAACCTCCTC CAATAATCCCACATCTCCTT
CCL5 GGATAGAGGGTTTCTTGATT GCTGATTTCTTGGGTTTG
CCR1 CACTCACCGTACCTGTAGCC TCTGATGATCCCTGCATAGC
CCR3 TCTGCTGAGATGTCCCAATA TCACCAACAAAGGCGTAG
MUC-5ac GTGTCGGCCGGAGAAAGTTGGT GTCCTGTTGAGCCTGGCCTGTG
Ym-1 CCAGCAGAAGCTCTCCAGAAGCA CAGCTGGTAGGAAGATCCCAGCTGT
Ym-2 TCCACTTTGAACCACATTCCAAGGC CGAGAGACTGAGACAGTTCAGGGA
AMCase-1 TGGACACACCTTCATCCTGA CCTCAGTGGCTCCACTTCTC
E-selecin CCCTTCCACAGAACCTACCA TCAGCAGACATTGCTTCACC
b-Actin CTGTCCCTGTATGCCTCTG ATGTCACGCACGATTTCC
doi:10.1371/journal.pone.0034634.t001
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responses to increasing dose (6.25 to 50 mg/ml) of aerosolized
methacholine. Results are expressed as a percentage of the
respective basal values.
RNA Preparation and Quantitative RT-PCR
Total RNA was isolated from lungs (5 mice in each group) using
the TRIzol reagent (SIGMA-Aldrich, St. Louis, USA). Real-time
PCR was performed on cDNA samples using the SYBR Green
system (Bio-Rad; Richmond, CA). Primers for inflammatory bio-
markers are shown in Table 1. Analysis was performed using the
sequence detection software supplied with the instrument. A
melting curve analysis was performed to control for the specificity
of the amplification products.
CD4+ T Cell Isolation and Th2 Differentiation
To obtain naive CD4+T cells, single cell suspensions were
prepared from spleens and treated with monoclonal antibodies to
CD4 coupled to magnetic beads according to the protocol
provided by the manufacturer. For Th2 differentiation, IL-2
(10 ng/ml), IL-4 (5 ng/ml) and anti-IFN-c (4 mg/ml) were added.
Cytokine Assays
Naive CD4+ T cells were stimulated for 72 h with anti-CD3
(5 mg/ml) plus anti-CD28 (2.5 mg/ml) and Th2 differentiated cells
were restimulated for 24 h with anti-CD3 (5 mg/ml) in the
presence/absence of farrerol (5 and 20 mg/l), after which
supernatants were collected and cytokine concentrations were
measured by ELISA using commercially available kits. Control
cells were incubated in medium alone for the duration of the
experiment. ELISA was also used to determine the levels of Th2
cytokines in BALF.
Western Blot Analysis of MAPK, NF-kB and PI3K
Lung tissues were added to lysis buffer and homogenized. Th2
cells (1610
6) were plated into 6-well plates and pretreated with 5
and 20 mg/L of farrerol, 1 h prior to a 1 h treatment with anti-
CD3 (5 mg/ml). Nuclear and cytoplasmic fractions of lung were
prepared as previously described [34]. Whole cell lysates were
prepared in 1% Non-diet P-40 lysis buffer with freshly added
protease and phosphatase inhibitors. Protein were separated by
SDS/PAGE and transferred onto PVDF membrane. Membranes
were probed for different antibodies.
Statistical Analysis
All values were expressed as means6the standard error of the
mean (SEM). Differences between mean values of normally
distributed data were assessed by the two-tailed Student t test.
Statistical difference was accepted at P,0.05.
Supporting Information
Figure S1 Effect of farrerol on production of inflamma-
tory cytokines TNF-a, IL-6 and IL-8 in the BALF of LPS-
induced ALI mice. Mice were given an oral administration of
farrerol 1 h prior to an i.n. administration of LPS. BALF was
collected at 6, 12 and 24 h following LPS challenge to analyze the
inflammatory cytokines TNF-a, IL-6 and IL-8. The values
presented are the means6SEM (n=5 in each group).
*p,0.05 vs. LPS group;
(TIF)
Figure S2 Effect of farrerol on Akt, P70S6K, NF-kB and
MAPK activation in vivo. Immunoblotting of Akt, NF-kB,
P70S6K, and MAPK in proteins extracts of lung tissues isolated
from mice 24 hours after the LPS challenge pretreated with 20 or
40 mg/kg farrerol. b-actin was used as an internal control.
Experiments were repeated three times and similar results were
obtained.
(TIF)
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